R. De Bock
University Hospital of Lausanne
6 Papers
241 Citations
R. De Bock is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Neutropenia & Piperacillin/tazobactam. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
A. Cometta,Stephen H. Zinner,R. De Bock,Thierry Calandra,H Gaya,Jean Klastersky,J Langenaeken,Marianne Paesmans,C Viscoli,M. P. Glauser +9 more
TL;DR: It is suggested that piperacillin-tazobactam plus amikacin is more effective than ceftazidime plus amkacin for the empiric treatment of fever and bacteremia in granulocytopenic cancer patients.
262
Monotherapy With Meropenem Versus Combination Therapy With Ceftazidime Plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients With Cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program
A. Cometta,Thierry Calandra,H Gaya,Stephen H. Zinner,R. De Bock,A Del Favero,G Bucaneve,F Crokaert,W V Kern,Jean Klastersky,I Langenaeken,A Micozzi,A Padmos,Marianne Paesmans,C Viscoli,M. P. Glauser +15 more
TL;DR: In this article, the efficacy, safety, and tolerance of meropenem monotherapy with those of the combination of ceftazidime plus amikacin for the empirical treatment of fever in granulocytopenic cancer patients were compared.
258
Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B
J. L. Harousseau,A. W. Dekker,A. Stamatoullas-Bastard,A. Fassas,W. Linkesch,J. Gouveia,R. De Bock,M. Rovira,W. Seifert,H. Joosen,M Peeters,K De Beule +11 more
TL;DR: A double-blind, double-placebo, randomized, multicenter trial was performed to compare the efficacy and safety of itraconazole oral solution with amphotericin B capsules for prophylaxis of systemic and superficial fungal infection among immunocompromised patients with hematological malignancy.
160
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
A. Cometta,Winfried V. Kern,R. De Bock,Marianne Paesmans,M. Vandenbergh,Françoise Crokaert,Dan Engelhard,Oscar Marchetti,Hamdi Akan,A. Skoutelis,Volkan Korten,M. Vandercam,H. Gaya,A. Padmos,Jean Klastersky,Stephen H. Zinner,M. P. Glauser,Thierry Calandra,C. Viscoli +18 more
TL;DR: This study failed to demonstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently febrile neutropenic patients with cancer.
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
C. Viscoli,A. Cometta,Winfried V. Kern,R. De Bock,Marianne Paesmans,Françoise Crokaert,M. P. Glauser,Thierry Calandra +7 more
TL;DR: It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia.